1. Search Result
Search Result
Isoforms Recommended: LIMK2
Results for "

LIMK2

" in MedChemExpress (MCE) Product Catalog:

25

Inhibitors & Agonists

1

Antibodies

3

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-18305
    BMS-5
    5 Publications Verification

    LIMKi 3

    LIM Kinase (LIMK) Cancer
    BMS-5 (LIMKi 3) is a potent LIMK inhibitor with IC50s of 7 nM and 8 nM for LIMK1 and LIMK2, respectively.
    BMS-5
  • HY-18832

    Ephrin Receptor Cancer
    AWL-II-38.3 is a potent ephrin-A receptor (EphA3) kinase inhibitor. AWL-II-38.3 does not exhibit significant cellular activity against Src-family kinases nor against b-raf [2] [2].
    AWL-II-38.3
  • HY-18304
    BMS-3
    3 Publications Verification

    LIM Kinase (LIMK) Cancer
    BMS-3 is a potent LIMK inhibitor with IC50s of 5 nM and 6 nM for LIMK1 and LIMK2, respectively.
    BMS-3
  • HY-122630
    TH-257
    1 Publications Verification

    LIM Kinase (LIMK) Cancer
    TH-257 is a potent inhibitor of LIMK1 and LIMK2 with IC50 values of 84 nM and 39 nM for LIMK1 and LIMK2, respectively, and it can be used as a chemical probe for LIMK1 and LIMK2. TH-257 is an allosteric inhibitor targeting a binding pocket induced by an αC and DFG-out conformation. TH257 is exquisitely selective and no significant activity against the wider kinome has been observed in the KINOMEscan assay at 1 μM .
    TH-257
  • HY-148065

    PROTACs Wee1 CDK AAK1 ULK MELK Itk IRAK Ephrin Receptor FGFR MAP4K p38 MAPK Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    FMF-06-098-1 is a multi-target kinase PROTAC degrader. FMF-06-098-1 can be used to target degradation kinases which degrades AAK1, AΒL2, AURKA, AURKB, BUBIB, CDC7, CDK1, CDK12, CDK13, CDK2, CDK4, CDk6, CDK7, CDK9, CHEK1, CSNKID, EPHA1, PER, FGFR1, GAK, IRAK4, ITK, LIMK2, MAP4K2, MAP4K3, MAPK6, MAPK7, MARK4, MELK, PKN3, PLK4, PRKAA1, PTK2, PTK6, RPS6KA4, S1K2, STK35, TNK2, UHMK1, ULK1, and WEE1 .
    FMF-06-098-1
  • HY-19352
    T56-LIMKi
    2 Publications Verification

    T5601640

    LIM Kinase (LIMK) Cancer
    T56-LIMKi is a selective inhibitor of LIMK2; inhibits the growth of Panc-1 cells with an IC50 of 35.2 μM.
    T56-LIMKi
  • HY-12659
    LX7101
    3 Publications Verification

    LIM Kinase (LIMK) ROCK PKA Endocrinology
    LX7101 is a potent LIM-kinase, ROCK and PKA inhibitor with IC50s of 24 nM, 1.6 nM, 10 nM and <1 nM for LIMK1, LIMK2, ROCK2 and PKA, respectively. LX7101 proves significantly selective for LIMK2 with IC50 values of 4.3 nM and 32 nM for LIMK2 and LIMK1 at 2 μM ATP, respectively. LX7101 has the potential for ocular hypertension and associated glaucoma research [2].
    LX7101
  • HY-14227

    LIM Kinase (LIMK) ROCK Others
    LIMK-IN-1 (Compound 14) is an inhibitor of LIM-Kinase (LIMK), with IC50s of 0.5 nM and 0.9 nM for LIMK1 and LIMK2, respectively. LIMK-IN-1 can be used for ocular hypertension and associated glaucoma research .
    LIMK-IN-1
  • HY-137346

    (S,R,S)-AHPC-Me-PEG2-dabrafenib

    PROTACs LIM Kinase (LIMK) CDK Cancer
    DD-03-156 is a potent and selective degrader of CDK17 and LIMK2. The selectivity and potency of DD-03-156 is exquisite and makes an advanced starting point for the development of a chemical probe for the degradation of CDK17 (Blue: VHL ligand (HY-112078), Black: linker HY-124380 (HY-124380);Pink: BRAF inhibitor (HY-14660)) .
    DD-03-156
  • HY-148062

    PROTACs CDK AAK1 Cyclin G-associated Kinase (GAK) Salt-inducible Kinase (SIK) LIM Kinase (LIMK) Wee1 SnRK Others
    RSS0680 is a small noncoding RNA (sRNA) targeting the mRNA ribosome binding site (RBS) and a PROTAC with protein kinase degradation activity (Pink: FLT3-IN-17 (HY-148070); Black: Linker (HY-W041970); Blue: E3 ligase Ligand (HY-112078)). RSS0680 competitively binds to RBS through the conserved CCUCCUCCC anti-Shine-Dalgarno (aSD) sequence and inhibits the translation initiation of target genes. RSS0680 can interact with the DUF1127 protein CcaF1, regulate its own stability and participate in bacterial oxidative stress defense, enhancing the host's resistance to heat shock and oxidative damage by affecting pathways such as C1 metabolism and pyruvate dehydrogenase complex. RSS0680 degrades AAK1, CDK1, CDK16, CDK2, CDK4, CDK6, EIF2AK4, GAK, LATSl, LIMK2, MAPK6, MAPKAPK5, MARK2, MARK4, MKNK2, NEK9, RPS6KB1, SIK2, SNRK, STK17A, STK17B, STK35, and WEEl. RSS0680 can be used to study diseases or disorders mediated by aberrant kinase activity and regulatory mechanisms of noncoding RNAs in α-proteobacteria[1][2].
    RSS0680
  • HY-151539

    LIM Kinase (LIMK) Neurological Disease
    TH470 is a highly selective LIMK1/2 (LIM kinase1/2) inhibitor (LIMK1 IC50=9.8 nM; LIMK2 IC50=13 nM), and can be used in orphan disease research .
    TH470
  • HY-120025

    LIM Kinase (LIMK) Cancer
    CRT0105950 is a potent LIMK inhibitor, with IC50s of 0.3 nM and 1 nM for LIMK1 and LIMK2 respectively. CRT0105950 can be used for the research of cancer .
    CRT0105950
  • HY-RS07666

    Small Interfering RNA (siRNA) LIM Kinase (LIMK) Others

    Limk2 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Limk2 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Limk2 Mouse Pre-designed siRNA Set A
    Limk2 Mouse Pre-designed siRNA Set A
  • HY-178122

    LIM Kinase (LIMK) Cancer
    THNAN69 is a potent chemical probe degrader targeting LIMK2, with a DC50 value of 1 nM. THNAN69 can be used for the study of diseases driven by LIMK2 overexpression or dysregulation, such as cancers and ocular diseases .
    THNAN69
  • HY-E70841

    LIM Kinase (LIMK) Cancer
    LIM kinase 2 (LIMK2) is a serine/threonine and tyrosine kinases. LIMK2 plays a crucial role in the regulation of cytoskeleton dynamics by controlling actin filaments and microtubule turnover, especially through the phosphorylation of cofilin, an actin depolymerising factor. LIMK2 Recombinant Human Active Protein Kinase is a recombinant LIMK2 protein that can be used to study LIMK2-related functions .
    LIMK2 Recombinant Human Active Protein Kinase
  • HY-RS07667

    Small Interfering RNA (siRNA) LIM Kinase (LIMK) Others

    Limk2 Rat Pre-designed siRNA Set A contains three designed siRNAs for Limk2 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Limk2 Rat Pre-designed siRNA Set A
    Limk2 Rat Pre-designed siRNA Set A
  • HY-RS07665

    Small Interfering RNA (siRNA) LIM Kinase (LIMK) Others

    LIMK2 Human Pre-designed siRNA Set A contains three designed siRNAs for LIMK2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    LIMK2 Human Pre-designed siRNA Set A
    LIMK2 Human Pre-designed siRNA Set A
  • HY-174229

    LIM Kinase (LIMK) Neurological Disease Cancer
    SM311 (Compound 10), a chemical probe, is a potent selective irreversible LIMK1 inhibitor (EC50=0.045 μM, >30-fold selective over LIMK2). SM311 blocks cofilin phosphorylation and actin cytoskeleton regulation. SM311 is promising for research of neurodegenerative diseases like Fragile X syndrome (FXS) and Alzheimer’s disease, as well as tumor invasion .
    SM311
  • HY-135843

    LIM Kinase (LIMK) Cancer
    TH-263, a diaryl sulfonamide derivative, is inactive toward both LIMK1 and LIMK2 and thus can be used as negative control for TH-257 .
    TH-263
  • HY-175656

    LIM Kinase (LIMK) Neurological Disease Cancer
    MDI-117740 is a dual LIMK1/2 inhibitor. MDI-117740 shows effective cellular target engagement with LIMK1 (pIC50 = 6.73) and LIMK2 (pIC50 = 7.18) in HEK293 cells. MDI-117740 exerts significant anti-migratory activity in MDA-MB-231 cells. MDI-117740 can be used for the study of cancers and neurodegenerative disorders .
    MDI-117740
  • HY-168908

    LIM Kinase (LIMK) Cancer
    LIJTF500025, a chemical probe, is a potent and selective LIMK inhibitor, with pIC50 values of 6.77 and 7.03 for LIMK1 and LIMK2, respectively, as determined by NanoBRET. LIJTF500025 can be used for the research of cancer .
    LIJTF500025
  • HY-12659B

    LIM Kinase (LIMK) ROCK PKA Endocrinology
    LX7101 monohydrochloride is a potent LIM-kinase, ROCK and PKA inhibitor with IC50s of 24 nM, 1.6 nM, 10 nM and <1 nM for LIMK1, LIMK2, ROCK2 and PKA, respectively. LX7101 monohydrochloride proves significantly selective for LIMK2 with IC50 values of 4.3 nM and 32 nM for LIMK2 and LIMK1 at 2 μM ATP, respectively. LX7101 monohydrochloride has the potential for ocular hypertension and associated glaucoma research [2].
    LX7101 monohydrochloride
  • HY-14226

    LIM Kinase (LIMK) Neurological Disease
    LIMK-IN-3 (Compound 33) is a LIMK2 inhibitor (IC50: 1.2 nM). LIMK-IN-3 can be used for glaucoma research .
    LIMK-IN-3
  • HY-125444

    LIM Kinase (LIMK) Neurological Disease Cancer
    TH251 is a LIMK1 and LIMK2 inhibitor with IC50s of 52 nM and 47 nM against LIMK1 and LIMK2, respectively. TH251 binds to inactive αC-out and DFG-out LIMK1 conformations, inhibits unphosphorylated LIMK1 and LIMK2 enzymatic activity, and exhibits unchanged potency despite PAK-mediated phosphorylation of either kinase. TH251 can be used for the research of cancers, glaucoma, and CNS diseases [2].
    TH251
  • HY-182103

    MAP3K Caspase p38 MAPK Cardiovascular Disease
    ZAK-IN-2 (Compound 8) is a selective, covalent ZAK inhibitor with an IC50 of 11.5 nM. ZAK-IN-2 forms a covalent bond with Cys22 in the P-loop of ZAK to inhibit its kinase activity. ZAK-IN-2 inhibits the phosphorylation of the downstream target p38. ZAK-IN-2 blocks Doxorubicin (HY-15142A)-induced cleavage of Caspase 3. ZAK-IN-2 is applicable to research related to myocardial hypertrophy .
    ZAK-IN-2

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: